Home The Word Brain My Amedeo FAQ Privacy About   

2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.

  Lung Cancer

  Free Subscription


1 Ann Surg Oncol
1 Arch Bronconeumol
5 BMC Cancer
1 Cancer
1 Cancer Cell
1 Cancer Chemother Pharmacol
2 Cancer Res
2 Chest
3 Clin Cancer Res
1 Clin Lung Cancer
3 Eur J Cancer
3 Eur J Cardiothorac Surg
1 Genes Chromosomes Cancer
1 J Cancer Res Clin Oncol
2 J Clin Oncol
2 J Thorac Cardiovasc Surg
1 J Thorac Oncol
5 Lung Cancer
1 Oncologist
1 PLoS One

  Retrieve available abstracts of this week’s articles:
HTML format
Single Articles

    Ann Surg Oncol

  1. WEI W, Wang Y, Ouyang R, Wang T, et al
    Machine Learning for Early Discrimination Between Lung Cancer and Benign Nodules Using Routine Clinical and Laboratory Data.
    Ann Surg Oncol. 2024 Jul 16. doi: 10.1245/s10434-024-15762.
    PubMed         Abstract available

    Arch Bronconeumol

  2. DAUNGSUPAWONG H, Wiwanitkit V
    Radiomics and Clinical Data for the Diagnosis of Incidental Pulmonary Nodules and Lung Cancer Screening: Correspondence.
    Arch Bronconeumol. 2024 Jul 8:S0300-2896(24)00239.

    BMC Cancer

  3. WANG Y, Chen R, Guo Z, Wei W, et al
    Immunological profiling for short-term predictive analysis in PD-1/PD-L1 therapy for lung cancer.
    BMC Cancer. 2024;24:851.
    PubMed         Abstract available

  4. WU G, Liu J, Shi H, Pan B, et al
    The associations between dysregulation of human blood metabolites and lung cancer risk: evidence from genetic data.
    BMC Cancer. 2024;24:854.
    PubMed         Abstract available

  5. CHEN Y, Wu S, Han Y, Shi H, et al
    LncRNA SH3PXD2A-AS1 facilitates cisplatin resistance in non-small cell lung cancer by regulating FOXM1 succinylation.
    BMC Cancer. 2024;24:848.
    PubMed         Abstract available

  6. YAMAGUCHI T, Shimizu J, Matsuzawa R, Watanabe N, et al
    Efficacy of chemotherapy plus immune checkpoint inhibitors in patients with non-small cell lung cancer who have rare oncogenic driver mutations: a retrospective analysis.
    BMC Cancer. 2024;24:842.
    PubMed         Abstract available

  7. BIAN Y, Liu H, Huang J, Feng Z, et al
    eHSP90alpha in front-line therapy in EGFR exon 19 deletion and 21 Leu858Arg mutations in advanced lung adenocarcinoma.
    BMC Cancer. 2024;24:835.
    PubMed         Abstract available


  8. MAKAREM M, Janne PA
    Top advances of the year: Targeted therapy for lung cancer.
    Cancer. 2024 Jun 21. doi: 10.1002/cncr.35423.
    PubMed         Abstract available

    Cancer Cell

  9. DUPLAQUET L, So K, Ying AW, Pal Choudhuri S, et al
    Mammalian SWI/SNF complex activity regulates POU2F3 and constitutes a targetable dependency in small cell lung cancer.
    Cancer Cell. 2024 Jul 17:S1535-6108(24)00237-X. doi: 10.1016/j.ccell.2024.
    PubMed         Abstract available

    Cancer Chemother Pharmacol

  10. YAMAMOTO N, Koyama T, Sato J, Yoshida T, et al
    Phase I study of the anti-TIGIT antibody tiragolumab in combination with atezolizumab in Japanese patients with advanced or metastatic solid tumors.
    Cancer Chemother Pharmacol. 2024;94:109-115.
    PubMed         Abstract available

    Cancer Res

  11. LI J, Luo L, He J, Yu J, et al
    A Virus-Inspired Inhalable Liponanogel Induces Potent Antitumor Immunity and Regression in Metastatic Lung Tumors.
    Cancer Res. 2024;84:2352-2363.
    PubMed         Abstract available

  12. OATMAN N, Gawali MV, Congrove S, Caceres R, et al
    A multimodal drug-diet-immunotherapy combination restrains melanoma progression and metastasis.
    Cancer Res. 2024 Jun 17. doi: 10.1158/0008-5472.CAN-23-1635.
    PubMed         Abstract available


  13. SWEETNAM JM, Goldman L, Grimm L, Silvestri GA, et al
    Two Birds with One Stone: Cross-registry Analysis of Women Undergoing Lung Cancer and Breast Cancer Screening.
    Chest. 2024 Jul 10:S0012-3692(24)04606-3. doi: 10.1016/j.chest.2024.06.3798.

  14. TAKAMORI S, Osoegawa A, Hashinokuchi A, Karashima T, et al
    Role of Pathological Single- and Multiple-N Descriptors in Resected Non-small Cell Lung Cancer.
    Chest. 2024 Jul 12:S0012-3692(24)04605-1. doi: 10.1016/j.chest.2024.06.3797.
    PubMed         Abstract available

    Clin Cancer Res

  15. PENG X, Zhao H, Ye L, Hou F, et al
    Biomarker identification and risk prediction model development for differentiated thyroid carcinoma lung metastasis based on primary lesion proteomics.
    Clin Cancer Res. 2024 May 9. doi: 10.1158/1078-0432.CCR-23-3806.
    PubMed         Abstract available

  16. SUVILESH KN, Manjunath Y, Nussbaum YI, Gadelkarim M, et al
    Targeting AKR1B10 by drug repurposing with epalrestat overcomes chemoresistance in non-small cell lung cancer patient-derived tumor organoids.
    Clin Cancer Res. 2024 Jul 17. doi: 10.1158/1078-0432.CCR-23-3980.
    PubMed         Abstract available

  17. REINMUTH N, Juan-Vidal O, Kowalski D, Bryl M, et al
    Novel Combinations of Immunotherapies or DNA Damage Repair Inhibitors in Platinum-Refractory Extensive-Stage Small-Cell Lung Cancer: The Phase II BALTIC Study.
    Clin Cancer Res. 2024 Jul 17. doi: 10.1158/1078-0432.CCR-24-0013.
    PubMed         Abstract available

    Clin Lung Cancer

  18. KELTNER S, Esslinger H, Wu X, Rai S, et al
    Refining Surveillance Guidelines after Stereotactic Body Radiation Therapy for Early-Stage Lung Cancer.
    Clin Lung Cancer. 2024 Jun 21:S1525-7304(24)00134.
    PubMed         Abstract available

    Eur J Cancer

  19. TOUBLANC AC, Faure M, Verdy G, Rabeau A, et al
    Prospective cardiovascular events in patients with advanced thoracic cancer treated with immune checkpoint inhibitor.
    Eur J Cancer. 2024;207:114191.
    PubMed         Abstract available

  20. KRON A, Scheffler M, Wiesweg M, Hummel HD, et al
    Indirect comparison of capmatinib treatment from GEOMETRY mono-1 trial to SOC in German patients with locally advanced or metastatic NSCLC harboring METex14 skipping mutations.
    Eur J Cancer. 2024;207:114158.
    PubMed         Abstract available

  21. ANDERSEN L, Kisistok J, Henriksen TV, Bramsen JB, et al
    Exploring the biology of ctDNA release in colorectal cancer.
    Eur J Cancer. 2024;207:114186.
    PubMed         Abstract available

    Eur J Cardiothorac Surg

  22. LANGERON M, Khen-Dunlop N, Helfre S, Sarnacki S, et al
    Efficacy of an expandable prosthesis placement after left pneumonectomy for soft tissue Ewing sarcoma in a 5-year-old child: 10 years follow-up.
    Eur J Cardiothorac Surg. 2024;66:ezae259.
    PubMed         Abstract available

  23. TREASURE T, Macbeth F, Fallowfield L
    Reply to Michael Poullis about lung metastasectomy.
    Eur J Cardiothorac Surg. 2024;66:ezae274.

    Pulmonary metastasectomy-back to basic biology.
    Eur J Cardiothorac Surg. 2024;66:ezae272.

    Genes Chromosomes Cancer

  25. YU L, Liu J, Jia J, Yang J, et al
    Fusion Genes Landscape of Lung Cancer Patients From Inner Mongolia, China.
    Genes Chromosomes Cancer. 2024;63:e23258.
    PubMed         Abstract available

    J Cancer Res Clin Oncol

  26. FOTOPOULOS I, Nguyen OTD, Nost TH, Markaki M, et al
    Promising microRNAs in pre-diagnostic serum associated with lung cancer up to eight years before diagnosis: a HUNT study.
    J Cancer Res Clin Oncol. 2024;150:355.
    PubMed         Abstract available

    J Clin Oncol

  27. BLAKELY CM, Urisman A, Gubens MA, Mulvey CK, et al
    Neoadjuvant Osimertinib for the Treatment of Stage I-IIIA Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer: A Phase II Multicenter Study.
    J Clin Oncol. 2024 Jul 19:JCO2400071. doi: 10.1200/JCO.24.00071.
    PubMed         Abstract available

  28. KAPADIA P, Zimolzak AJ, Upadhyay DK, Korukonda S, et al
    Development and Implementation of a Digital Quality Measure of Emergency Cancer Diagnosis.
    J Clin Oncol. 2024;42:2506-2515.
    PubMed         Abstract available

    J Thorac Cardiovasc Surg

  29. SMITH R JR, Gee KN, Kalvapudi S, Pachimatla A, et al
    Sex-based Differences in the Lung Immune Microenvironment Are Associated with an Increased Risk of Lung Cancer in Women.
    J Thorac Cardiovasc Surg. 2024 Jul 15:S0022-5223(24)00617.
    PubMed         Abstract available

  30. WATKINS AA, Rizvi TZ, Lopez E, Shehata D, et al
    Trends and Comparative Outcomes Between Operative Approaches for Segmentectomy in Lung Cancer.
    J Thorac Cardiovasc Surg. 2024 Jul 11:S0022-5223(24)00605.
    PubMed         Abstract available

    J Thorac Oncol

  31. GRAY JE, Markovets A, Reungwetwattana T, Majem M, et al
    Longitudinal Analyses of Circulating-Tumor DNA for Detection of EGFR Mutation-Positive Advanced Non-Small Cell Lung Cancer Progression During Treatment: Data From FLAURA and AURA3.
    J Thorac Oncol. 2024 Jul 17:S1556-0864(24)00676.
    PubMed         Abstract available

    Lung Cancer

  32. ASAO T, Shukuya T, Uemura K, Kitadai R, et al
    Risk and survival of patients with non-small cell lung cancer and pre-existing autoimmune disorders receiving immune checkpoint blockade therapy: Survival analysis with inverse probability weighting from a nationwide, multi-institutional, retrospectiv
    Lung Cancer. 2024;194:107894.
    PubMed         Abstract available

  33. BELLUOMINI L, Cesta Incani U, Smimmo A, Avancini A, et al
    Prognostic impact of Interleukin-8 levels in lung cancer: A meta-analysis and a bioinformatic validation.
    Lung Cancer. 2024;194:107893.
    PubMed         Abstract available

  34. ZANDWIJK NV, Frank AL, Reid G, Dimitri Roe O, et al
    Asbestos-Related lung Cancer: An underappreciated oncological issue.
    Lung Cancer. 2024;194:107861.
    PubMed         Abstract available

  35. JACOB M, Fournel P, Tissot C, Cadranel J, et al
    A prospective analysis of the management practices for patients with Stage-III-N2Non-Small-Cell lung cancer (OBSERVE IIIA-B GFPC 04-2020Study).
    Lung Cancer. 2024;194:107868.
    PubMed         Abstract available

  36. IZUMI M, Costa DB, Kobayashi SS
    Targeting of drug-tolerant persister cells as an approach to counter drug resistance in non-small cell lung cancer.
    Lung Cancer. 2024;194:107885.
    PubMed         Abstract available


  37. MEYER ML, Hirsch FR, Bunn PA, Ujhazy P, et al
    Calls to action on lung cancer management and research.
    Oncologist. 2024 Jul 13:oyae169. doi: 10.1093.
    PubMed         Abstract available

    PLoS One

  38. VAN DEN BOSSCHE J, De Laere M, Deschepper K, Germonpre P, et al
    Integration of the PD-L1 inhibitor atezolizumab and WT1/DC vaccination into standard-of-care first-line treatment for patients with epithelioid malignant pleural mesothelioma-Protocol of the Immuno-MESODEC study.
    PLoS One. 2024;19:e0307204.
    PubMed         Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Lung Cancer is free of charge.